Onychomycosis of Toenail
Conditions
Keywords
DSO, toenail, onychomycosis
Brief summary
This is a 52 week, 20-patient open-label pilot study on the safety and efficacy of Next Science Wound gel in the treatment of mild to moderate Distal Subungual Onychomycosis.
Detailed description
Patients will apply Next Science Wound Gel daily to each study treatment hallux nail for 48 weeks once approved for participation. Analysis will be attained via potassium hydroxide examination (KOH test), nail culture, PCR analysis, and photographic imaging. Subjects may have both hallux nails sampled at screening for culture and KOH testing if both hallux nails appear to meet the criteria for study inclusion. Only subjects with both a positive culture and KOH examination will start study treatment. Subjects may have repeat KOH and culture testing both performed if the first screening test results in at least one of the tests being negative. At investigator's discretion, other affected toenails besides the study target hallux nail may be treated but will not be included for analysis. Patients will come for in-clinic visits at screening, baseline/randomization visit/week 0, week 4, week 8, week 12, week 24, week 36, week 48, and week 52. If subjects achieve complete cure (as defined by mycological cure and 0% nail involvement) prior to Week 48, patients will be encouraged to continue in the trial with active treatment for the full protocol.
Interventions
DEVICENext Science Treatment Gel
Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
Sponsors
Doctors Research Network
Tissue Analytics
NTS Ventures
Next Science TM
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ages 18 years old and above 2. Established and active diagnosis of distal subungual onychomycosis of at least one hallux nail affecting 20-75% of the hallux nail 3. Positive culture for dermatophytes and positive potassium hydroxide examination 4. Provide signed and dated informed consent 5. Willing to comply with all study procedures and available for the duration of the study
Exclusion criteria
1. Known allergic reaction to the study products 2. Unable to provide signed and dated informed consent form 3. Unable or unwilling to comply with all study procedures and/or unavailable for duration of the study 4. Thickness of mycotic nail is greater than 3mm 5. Less than 2mm of clear nail at the proximal aspect 6. History of rheumatoid arthritis 7. Subject with any other disease or condition other than DSO that would affect nail appearance or interfere with image analysis 8. Unwilling or unable to limit use of nail polish for duration of study 9. Known history of PVD, immune system concerns, or ongoing chemotherapy 10. Severe moccasin tinea pedis 11. Prior systemic antifungal drugs 6 months before study start date 12. Prior topical therapy for toenail fungus 2 months before study start date 13. Any diseases or circumstances in which the patient should not participate in the study in the opinion of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mycological Cure at 48 Weeks | Baseline to 48 Weeks | Mycological cure rate at week 48 as defined by negative potassium hydroxide examination and negative culture of the target hallux nail |
| Clinical Efficacy at 48 Weeks | Baseline to 48 Weeks | Clinical efficacy rate at week 48 as defined by less than 10% clinical involvement of the target hallux nail |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Almost Complete Cure at Week 48 | Baseline to 48 Weeks | Almost complete cure rate at week 48 defined as less than 10% clinical involvement, negative potassium hydroxide examination, and negative culture of the target hallux nail at week 48 |
| Almost Complete Cure at Week 52 | Baseline to Week 52 | Almost complete cure rate at week 52 defined as less than 10% clinical involvement, negative potassium hydroxide examination, and negative culture of the target hallux nail at Week 52 |
| Time to Complete Cure | Baseline to 52 Weeks | Measured across all observation points |
| Time to Almost Complete Cure | Baseline to 52 Weeks | Measured across all observation points |
| Complete Cure at Week 48 | Baseline to 48 Weeks | Complete cure rate at week 48 defined as 0% clinical involvement, negative potassium hydroxide examination and negative culture of the target hallux nail |
| Growth of Clear Nail | Baseline to 52 Weeks | Change in area of clear nail growth measured across all observation points |
| Mycological Cure Rate | Baseline to 52 Weeks | Changes in mycological cure rates (Changes in the proportion of subjects who achieved mycological cure, defined as negative culture and potassium hydroxide examination) measured across all observation points |
| Dermatopyhyte Identification and Characterization | Baseline to 52 Weeks | Changes in the types of dermatophytes dermatophytes across all observation points |
| Overall Fungal Species | Baseline to 52 Weeks | Change types of overall fungal species across all observation points |
| Percent Change in Area of Nail Involvement | Baseline to 52 Weeks | Calculated as a ratio of clear to involved measured across all observation points |
| Complete Cure at Week 52 | Baseline to 52 Weeks | Complete cure rate at week 52 defined as 0% clinical involvement, negative mycology, and negative potassium hydroxide examination of the target hallux nail at week 52 |
Countries
United States
Contacts
Primary ContactDianne Porral
Outcome results
None listed